Novavax NVAX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $596.34M-46.9% | $1.12B+5.5% | $1.06B-1.3% | $1.08B-14.0% | $1.25B+84.0% | ||
| $89.62M+22.7% | $73.04M-16.6% | $87.61M-30.9% | $126.73M-19.6% | $157.65M-22.2% | ||
| $506.72M-51.8% | $1.05B+7.5% | $977.05M+2.6% | $951.99M-13.2% | $1.1B+129% | ||
| 85%-8.5pp | 93.5%+1.7pp | 91.8%+3.5pp | 88.3%+0.8pp | 87.4%+17.2pp | ||
| $348.86M+1.9% | $342.32M-7.7% | $370.82M+3.1% | $359.71M-7.2% | $387.43M-1.0% | ||
| $138.17M-12.3% | $157.48M-21.9% | $201.7M-16.2% | $240.79M— | —— | ||
| $674.49M+0.6% | $670.68M-11.4% | $757.17M+4.1% | $727.23M-13.8% | $843.55M-9.4% | ||
| -$78.15M-117% | $452.8M+47.3% | $307.49M-12.5% | $351.49M-14.6% | $411.41M+265% | ||
| -13.1%-53.4pp | 40.3%+11.4pp | 28.9%-3.7pp | 32.6%-0.2pp | 32.8%+69.3pp | ||
| $21.73M-3.6% | $22.55M-7.2% | $24.31M+5.4% | $23.06M+6.3% | $21.69M+8.0% | ||
| $42.4M+4.4% | $40.63M-8.2% | $44.27M-13.2% | $51.02M+8.9% | $46.84M+15.8% | ||
| —— | $0-100% | $12.99M-50.0% | $25.97M-33.3% | $38.96M-25.0% | ||
| -$86.19M-119% | $442.17M+26.1% | $350.68M-18.7% | $431.39M-11.7% | $488.52M+377% | ||
| $1.65M-11.5% | $1.87M-79.1% | $8.94M+4.4% | $8.56M-12.8% | $9.82M-9.8% | ||
| -$87.84M-120% | $440.3M+28.8% | $341.75M-19.2% | $422.82M-11.7% | $478.7M+355% | ||
| -14.7%-53.9pp | 39.2%+7.1pp | 32.1%-7.1pp | 39.2%+1.1pp | 38.1%+65.6pp | ||
| -$0.64-127% | $2.35+32.0% | $1.78-21.6% | $2.27-14.0% | $2.64+297% | ||
| -$0.54-120% | $2.74+29.9% | $2.11-18.8% | $2.60-14.2% | $3.03+344% | ||
| 675.9M-2.1% | 690.3M+3.1% | 669.4M+0.3% | 667.1M+1.7% | 655.7M+6.1% | ||
| 649.6M+0.3% | 647.4M+1.5% | 637.6M+0.4% | 635.3M+2.2% | 621.7M+3.5% | ||
| —— | $0-100% | $12.99M-50.0% | $25.97M-33.3% | $38.96M-25.0% | ||
| $42.4M+4.4% | $40.63M-8.2% | $44.27M-13.2% | $51.02M+8.9% | $46.84M+15.8% | ||
| -$78.15M-117% | $452.8M+47.3% | $307.49M-12.5% | $351.49M-14.6% | $411.41M+265% | ||
| -$55.81M-112% | $480.41M+40.3% | $342.49M-12.8% | $392.61M-13.9% | $456.1M+328% | ||
| -$55.81M-112% | $480.41M+40.3% | $342.49M-12.8% | $392.61M-13.9% | $456.1M+328% | ||
| -9.4%-52.1pp | 42.8%+10.6pp | 32.2%-4.2pp | 36.4%+0.1pp | 36.3%+65.7pp | ||
| -$78.15M-117% | $452.8M+47.3% | $307.49M-12.5% | $351.49M-14.6% | $411.41M+265% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Novavax's revenue?
- Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.
- Is Novavax profitable?
- Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.
- What are Novavax's profit margins?
- Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.
- What is Novavax's earnings per share?
- Novavax's diluted EPS over the trailing twelve months is $-0.64.
- Where does Novavax's income statement data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
